Veeva Systems, a key life sciences industry cloud player, is acquiring Crossix, makers of a patient data and analytics platform used by pharmaceutical marketers. The $430 million cash deal is meant to bring more expertise in patient data and data science into Veeva.
The Crossix analytics platform aims to improve marketing effectiveness for pharmaceutical brands. The platform connects health and non-health data for more than 300 million US patients, such as Rx, OTC, clinical, claims, consumer, hospital, and media data. The platform is touted for its best-in-class privacy safeguards.
Veeva said Crossix will operate as an independent business unit under its current brand led by Crossix CEO Asaf Evenhaim. The company will remain headquartered in New York and also maintain its operations in Israel and Belarus.
"Crossix has been the pioneer in patient data, privacy, and analytics," said Veeva CEO Peter Gassner. "As we look toward the future of a more patient-centric healthcare system, Asaf and I are excited to join forces to help the industry deliver better patient outcomes."
- Veeva's master plan: Bring cloud data warehouse and then AI to life sciences
- Cloud v. Data Center: Key trends for IT decision-makers
- Infographic: Cloud use is growing, but the data center isn't dead yet
- Has IT's default setting switched from data center to cloud?
- Understanding the pros and cons of five different cloud types
- Multi-cloud is a messy reality, but there's hope
- Six reasons why companies hang on to their data centers
- Five major pitfalls to avoid in a cloud migration
- How hybrid cloud is strengthening Fitness First